RankingsPricing
  1. US-listed companies
  2. ADMA BIOLOGICS, INC.

ADMA BIOLOGICS, INC.ADMA

Market cap
$4.4B
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
NET LOSS-7,301,313-15,527,246-16,813,163-17,969,930-19,515,151-43,758,975-65,743,445-48,279,317-75,748,548-71,647,618-65,903,950-28
Depreciation and amortization182,089210,633247,852469,821469,5763334578
Loss on disposal of fixed assets-18,399-----10,144-122,190-207,07181,697-220,761-426,536-0
Interest paid in kind----------34
Stock-based compensation626,787888,2951212233356
Amortization of debt discount2,86991,704133,197353,635676,943781,567112223
Loss on extinguishment of debt----719,097--1,210,216--9,962,495991,797--6,669,941-26
Amount of noncash revenue related to amortization of license revenue.---------142,834-142,834-142,834-0
Accounts receivable-39,11239,112383,961540,50793,5593-2,487,7132-9,767,37115-13,071,80912
Inventories118,248403,46539,70422-589,318635-28,470,864433910
Prepaid expenses and other current assets---------1755,9000
Amount of increase (decrease) in deposits and operating assets classified as other.---------2-122,468-1
Accounts payable-244,7432-937,779308,658476,8263-20,480321799,9814
Accrued expenses150,62276,4711-199,615416,972614,483406,984806,3533888
Other current and non-current liabilities------174,434-190,514-218,580-502,238-1
Net cash provided by (used in) operating activities-6,903,795-10,887,154-14,704,910-15,418,404-18,268,973-37,271,774-62,678,682-76,193,504-102,002,958-112,368,982-59,508,2579
Purchase of property and equipment118,853196,635226,07373,4103241314145
Net cash used in investing activities-118,853-3,131,819-4,040,743-1,741,575904,58315-2,095,600-3,811,838-12,724,680-13,511,258-13,911,171-5
Acquisition of intangible assets-----------0
Net cash used in investing activities-118,853-3,131,819-4,040,743-1,741,575904,58315-2,095,600-3,811,838-12,724,680-13,511,258-13,911,171-5
Principal payments on notes payable200,000--15-20-30--100159
Proceeds from issuance of common stock, net of offering expenses1727-101439434813112165-
The cash outflow for payment of debt refinancing fees.---------830,000-211
Proceeds from issuance of note payable41,000,00010-------152135
Amount of cash outflow related to taxes on vested Restricted Stock Units.---------61,59831
Payments on finance lease obligations---------34,29936,6840
Net proceeds from the exercise of stock options---49,227-7,50413,00775,04813,432-175,0151
Payment of deferred financing fees----------32
Amount of cash outflow for end of term fee.-----------2
Net cash (used in) provided by financing activities1928101017614380144121109-39
Payment of deferred financing fees----------32
Net cash (used in) provided by financing activities1928101017614380144121109-39
Net (decrease) increase in cash and cash equivalents----------4,832,03435-35